Medical and Pharmaceutical Kairos Pharma gets US$876K DoD grant for lung cancer treatment resistance research The company has developed an antibody to fight against a protein that makes lung cancer cells resistant to drugs Rowan Dunne1 day ago
Medical and Pharmaceutical Alarming CT radiation study highlights need for alternative diagnostic tools University of California researchers have determined that these machines can cause 1 out of every 20 new cancer cases Rowan Dunne3 days ago
Medical and Pharmaceutical How could a simple blood test could eliminate tumour biopsies? The company has received support from the Centre of Expertise in Advanced Materials and Sustainability and Innovate UK Joseph Morton3 days ago
Medical and Pharmaceutical Lung cancer breath test demonstrates remarkable efficacy in Dutch study It correctly identified positive cases with 80 to 92% accuracy Rowan Dunne4 days ago
Medical and Pharmaceutical Smokers skipping lung cancer screenings: study Lung cancer remains the leading cause of cancer death in the United States Joseph MortonApril 10, 2025
Medical and Pharmaceutical 60 Degrees Pharma signs patent agreement with Yale for tick disease medicine development The newly announced partnership sent shares up by 137% at the intraday peak on the Nasdaq Tuesday Rowan DunneApril 8, 2025
Medical and Pharmaceutical Long overdue lung cancer screening program coming to PEI, health minister says It will get phased in within the next 2 years Rowan DunneApril 8, 2025
Medical and Pharmaceutical Former nuclear test site workers advised to get screened for lung cancer The Worker Health Protection Program's screening initiative has helped catch cases linked to radiation exposure in their early stages Rowan DunneApril 7, 2025
Medical and Pharmaceutical Median Technologies clears hurdle on the way to regulatory acceptance in EU and US The company has met a key requirement for regulatory submissions in the US and Europe Joseph MortonApril 3, 2025
Medical and Pharmaceutical Corcept Therapeutics shares double on solid Phase 3 results for ovarian cancer treatment Relacorilant is designed to address disorders linked to the stress hormone cortisol Joseph MortonMarch 31, 2025